A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (STRATOS2)
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Sponsor: AstraZeneca
A PHASE3 clinical study on Uncontrolled Asthma, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 14 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Apr 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Apr 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .